Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats

Analyzing real-time PCR data by the comparative CT method

Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190 · see citing works

Identification of a nuclear receptor for bile acids

Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714 · see citing works

Revising consensus in portal hypertension: Report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension

de Franchis, R. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.06.004 · Cited by 2,291 · see citing works

Bile Acids: Natural Ligands for an Orphan Nuclear Receptor

Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274 · see citing works

Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation

Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678 · see citing works

Molecular Basis for Feedback Regulation of Bile Acid Synthesis by Nuclear Receptors

Lu, T. T., Makishima, M., Repa, J. J., Schoonjans, K., Kerr, T. A., Auwerx, J., & Mangelsdorf, D. J. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00050-2 · Cited by 1,487 · see citing works

Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase

Laufs, U., & Liao, J. K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.37.24266 · Cited by 1,035 · see citing works

Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease

Gadaleta, R. M., van Erpecum, K. J., Oldenburg, B., Willemsen, E. C. L., Renooij, W., Murzilli, S., Klomp, L. W. J., Siersema, P. D., Schipper, M. E. I., Danese, S., et al. (2011) · Gut · doi:10.1136/gut.2010.212159 · Cited by 870 · cited 1× · see citing works

6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity

Pellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743 · see citing works

Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage

Groszmann, R. J., Bosch, J., Grace, N. D., Conn, H. O., García–Tsao, G., Navasa, M., Alberts, J., Rodés, J., Fischer, R., Bermann, M., et al. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)91168-6 · Cited by 713 · see citing works

Nuclear Receptor-Dependent Bile Acid Signaling Is Required for Normal Liver Regeneration

Huang, W., Ma, K., Zhang, J., Qatanani, M., Cuvillier, J., Liu, J., Dong, B., Huang, X., & Moore, D. D. (2006) · Science · doi:10.1126/science.1121435 · Cited by 645 · see citing works

Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response

Wang, Y.-D., Chen, W.-D., Wang, M., Yu, D., Forman, B. M., & Huang, W. (2008) · Hepatology · doi:10.1002/hep.22519 · Cited by 639 · cited 1× · see citing works

Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis

Feu, F., García‐Pagán, J. C., Bosch, J., Luca, A., Escorsell, À., Rodés, J., & Terés, J. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91740-3 · Cited by 588 · see citing works

Clinical Course of Alcoholic Liver Cirrhosis: A Danish Population-Based Cohort Study

Jepsen, P., Ott, P., Andersen, P. K., Sørensen, H. T., & Vilstrup, H. (2009) · Hepatology · doi:10.1002/hep.23500 · Cited by 536 · see citing works

Deleterious Effects of Beta-Blockers on Survival in Patients With Cirrhosis and Refractory Ascites†,‡

Sersté, T., Mélot, C., Francoz, C., Durand, F., Rautou, P., Valla, D. C., Moreau, R., & Lebrec, D. (2010) · Hepatology · doi:10.1002/hep.23775 · Cited by 528 · see citing works

Hemodynamic Response to Pharmacological Treatment of Portal Hypertension and Long–Term Prognosis of Cirrhosis

Abraldeṣ, J. G., Tarantino, I., Turnés, J., García‐Pagán, J. C., Rodés, J., & Bosch, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50133 · Cited by 526 · see citing works

Propranolol for Prevention of Recurrent Gastrointestinal Bleeding in Patients with Cirrhosis

Lebrec, D., Poynard, T., Hillon, P., & Benhamou, J. (1981) · New England Journal of Medicine · doi:10.1056/nejm198112033052302 · Cited by 512 · see citing works

The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis

Fiorucci, S., Antonelli, E., Rizzo, G., Renga, B., Mencarelli, A., Riccardi, L., Orlandi, S., Pellicciari, R., & Morelli, A. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.08.001 · Cited by 472 · see citing works

The paradox of nitric oxide in cirrhosis and portal hypertension: Too much, not enough

Wiest, R., & Groszmann, R. J. (2002) · Hepatology · doi:10.1053/jhep.2002.31432 · Cited by 463 · see citing works

Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: Endothelial dysfunction in portal hypertension

Rockey, D. C., & Chung, J. J. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70487-1 · Cited by 408 · see citing works

Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis

Liu, Y., Binz, J. G., Numerick, M. J., Dennis, S., Luo, G., Desai, B., MacKenzie, K. I., Mansfield, T. A., Kliewer, S. A., Goodwin, B. J., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18945 · Cited by 398 · see citing works

Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat

Shah, V. H., Törüner, M., Haddad, F., Cadelina, G. W., Papapetropoulos, A., Choo, K. K., Sessa, W. C., & Groszmann, R. J. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70408-7 · Cited by 340 · see citing works

Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase

Trebicka, J., Hennenberg, M., Laleman, W., Shelest, N., Biecker, E., Schepke, M., Nevens, F., Sauerbruch, T., & Heller, J. (2007) · Hepatology · doi:10.1002/hep.21673 · Cited by 307 · see citing works

Propranolol in the Prevention of First Upper Gastrointestinal Tract Hemorrhage in Patients with Cirrhosis of the Liver and Esophageal Varices

Pascal, J., & Calès, P. (1987) · New England Journal of Medicine · doi:10.1056/nejm198710013171403 · Cited by 304 · see citing works

Functional aspects on the pathophysiology of portal hypertension in cirrhosis

García‐Pagán, J. C., Gracia‐Sancho, J., & Bosch, J. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.03.007 · Cited by 291 · see citing works

Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis

Zhang, S., Wang, J., Liu, Q., & Harnish, D. C. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.03.025 · Cited by 290 · see citing works

Isolated hepatic lipocytes and kupffer cells from normal human liver: Morphological and functional characteristics in primary culture

Friedman, S. L., Rockey, D. C., McGuire, R. F., Maher, J. J., Boyles, J. K., & Yamasaki, G. (1992) · Hepatology · doi:10.1002/hep.1840150211 · Cited by 284 · see citing works

Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: A multicenter survey on safety and efficacy

Laleman, W., Simón‐Talero, M., Maleux, G. A., Pérez, M., Ameloot, K., Soriano, G., Villalba, J., García‐Pagán, J. C., Barrufet, M., Jalan, R., et al. (2013) · Hepatology · doi:10.1002/hep.26314 · Cited by 279 · see citing works

Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis

Adorini, L., Pruzanski, M., & Shapiro, D. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.012 · Cited by 259 · see citing works

Farnesoid X Receptor Deficiency Induces Nonalcoholic Steatohepatitis in Low-Density Lipoprotein Receptor-Knockout Mice Fed a High-Fat Diet

Kong, B., Luyendyk, J. P., Tawfik, O. W., & Guo, G. L. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.144600 · Cited by 211 · see citing works

Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts

Fickert, P., Fuchsbichler, A., Moustafa, T., Wagner, M., Zollner, G., Halilbasic, E., Stöger, U., Arrese, M., Pizarro, M., Solís, N., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090114 · Cited by 169 · see citing works

Bile Acids Regulate Cardiovascular Function

Khurana, S., Raufman, J., & Pallone, T. L. (2011) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2011.00272.x · Cited by 152 · see citing works

Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers

Graupera, M., García‐Pagán, J. C., Abraldeṣ, J. G., Peralta, C., Bragulat, M., Corominola, H., Bosch, J., & Rodés, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50004 · Cited by 145 · see citing works

Increased Activation of the Wnt/β-Catenin Pathway in Spontaneous Hepatocellular Carcinoma Observed in Farnesoid X Receptor Knockout Mice

Wolfe, A. R., Thomas, A., Edwards, G., Jaseja, R., Guo, G. L., & Apte, U. M. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.179390 · Cited by 145 · see citing works

Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats

Pascoli, M. D., Diví, M., Rodrı́guez-Vilarrupla, A., Rosado, E., Gracia‐Sancho, J., Vilaseca, M., Bosch, J., & García‐Pagán, J. C. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.12.012 · Cited by 136 · see citing works

Portal hypertension: from pathophysiology to clinical practice

Laleman, W., Landeghem, L. V., Wilmer, A. P., Fevery, J., & Nevens, F. (2005) · Liver International · doi:10.1111/j.1478-3231.2005.01163.x · Cited by 131 · see citing works

FXR-mediated regulation of eNOS expression in vascular endothelial cells

Jiang, L., Wilson, A. S., Kuruba, R., Zhang, Q., Gao, X., He, F., Zhang, L., Pitt, B. R., Xie, W., & Song, L. (2007) · Cardiovascular Research · doi:10.1093/cvr/cvm016 · Cited by 123 · see citing works

Critical illness evokes elevated circulating bile acids related to altered hepatic transporter and nuclear receptor expression

Vanwijngaerden, Y.-M., Wauters, J., Langouche, L., Perre, S. V., Liddle, C., Coulter, S., Vanderborght, S., Roskams, T., Wilmer, A. P., den Berghe, G. V., et al. (2011) · Hepatology · doi:10.1002/hep.24582 · Cited by 96 · see citing works

In vivo gene transfer of endothelial nitric oxide synthase decreases portal pressure in anaesthetised carbon tetrachloride cirrhotic rats

de Casteele, M. V., Omasta, A., Janssens, S., Roskams, T., Desmet, V., Nevens, F., & Fevery, J. (2002) · Gut · doi:10.1136/gut.51.3.440 · Cited by 95 · see citing works

Natural History of Cirrhosis

Asrani, S. K., & Kamath, P. S. (2013) · Current Gastroenterology Reports · doi:10.1007/s11894-012-0308-y · Cited by 93 · see citing works

HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects

Klein, S., van Beuge, M. M., Granzow, M., Beljaars, L., Schierwagen, R., Kilic, S., Heidari, I., Huss, S., Sauerbruch, T., Poelstra, K., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.07.033 · Cited by 93 · see citing works

Farnesoid X Receptor Agonist Reduces Serum Asymmetric Dimethylarginine Levels through Hepatic Dimethylarginine Dimethylaminohydrolase-1 Gene Regulation

Hu, T., Chouinard, M. L., Cox, A. L., Sipes, P. R., Marcelo, M. C., FICORILLI, J. V., Li, S., Gao, H. T., Ryan, T. P., Michael, M. D., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606779200 · Cited by 83 · see citing works

A stable model of cirrhotic portal hypertension in the rat: thioacetamide revisited

Laleman, W., Elst, I. V., Zeegers, M., Servaes, R., Libbrecht, L. J., Roskams, T., Fevery, J., & Nevens, F. (2006) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2006.01620.x · Cited by 77 · see citing works

A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis†‡

Laleman, W., Omasta, A. K., de Casteele, M. V., Zeegers, M., Elst, I. V., Landeghem, L. V., Severi, T., van Pelt, J. F., Roskams, T., Fevery, J., et al. (2005) · Hepatology · doi:10.1002/hep.20968 · Cited by 73 · see citing works

Superoxide dismutase gene transfer reduces portal pressure in CCl 4 cirrhotic rats with portal hypertension

Laviña, B., Gracia‐Sancho, J., Rodrı́guez-Vilarrupla, A., Chu, Y., Heistad, D. D., Bosch, J., & García‐Pagán, J. C. (2008) · Gut · doi:10.1136/gut.2008.149880 · Cited by 73 · see citing works

Inhibition of eNOS phosphorylation mediates endothelial dysfunction in renal failure: new effect of asymmetric dimethylarginine

Kajimoto, H., Kai, H., Aoki, H., Yasuoka, S., Anegawa, T., Aoki, Y., Ueda, S., Okuda, S., & Imaizumi, T. (2012) · Kidney International · doi:10.1038/ki.2011.476 · Cited by 70 · see citing works

Inhibition of endothelin-1-mediated contraction of hepatic stellate cells by FXR ligand

Li, J., Kuruba, R., Wilson, A., Gao, X., Zhang, Y., & Li, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013955 · Cited by 66 · see citing works

Meta‐analysis: isosorbide‐mononitrate alone or with either beta‐blockers or endoscopic therapy for the management of oesophageal varices

Gluud, L. L., Langholz, E., & Krag, A. A. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04418.x · Cited by 63 · see citing works

Bench-to-beside review: Acute-on-chronic liver failure - linking the gut, liver and systemic circulation

Verbeke, L., Nevens, F., & Laleman, W. (2011) · Critical Care · doi:10.1186/cc10424 · Cited by 51 · see citing works

Nitroflurbiprofen, a Nitric Oxide-Releasing Cyclooxygenase Inhibitor, Improves Cirrhotic Portal Hypertension in Rats

Laleman, W., Landeghem, L. V., Elst, I. V., Zeegers, M., Fevery, J., & Nevens, F. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.12.041 · Cited by 51 · see citing works

Both Ca2+-dependent and -independent pathways are involved in rat hepatic stellate cell contraction and intrahepatic hyperresponsiveness to methoxamine

Laleman, W., Landeghem, L. V., Severi, T., Elst, I. V., Zeegers, M., Bisschops, R., van Pelt, J. F., Roskams, T., Cassiman, D. M., Fevery, J., et al. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00196.2006 · Cited by 42 · see citing works

Amelioration of portal hypertension and the hyperdynamic circulatory syndrome in cirrhotic rats by neuropeptide Y via pronounced splanchnic vasoaction

Moleda, L., Trebicka, J., Dietrich, P., Gäbele, E., Hellerbrand, C., Straub, R. H., Sauerbruch, T., Schöelmerich, J., & Wiest, R. (2011) · Gut · doi:10.1136/gut.2010.226407 · Cited by 38 · see citing works

FXR Agonist INT-747 Upregulates DDAH Expression and Enhances Insulin Sensitivity in High-Salt Fed Dahl Rats

Ghebremariam, Y. T., Yamada, K., Lee, J. C., Johnson, C. L. C., Atzler, D., Anderssohn, M., Agrawal, R., Higgins, J., Patterson, A. J., Böger, R. H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060653 · Cited by 26 · see citing works

Dimethylarginine dimethylaminohydrolase-2 overexpression improves impaired nitric oxide synthesis of endothelial cells induced by glycated protein

Lu, C.-W., Xiong, Y., & He, P. (2006) · Nitric Oxide · doi:10.1016/j.niox.2006.07.006 · Cited by 23 · see citing works

Microparticles and Paracrine Signaling in Portal Hypertension: Crucial Conversations or Idle Chat?

García‐Pagán, J. C., & Shah, V. H. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.016 · Cited by 2 · see citing works

Changes of Intestinal Functions in Liver Cirrhosis

Fukui, H., & Wiest, R. (2016) · Inflammatory Intestinal Diseases · doi:10.1159/000444436 · Cited by 6,820 · see citing works

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial

Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237 · see citing works

Hepatic stellate cells as key target in liver fibrosis

Higashi, T., Friedman, S. L., & Hoshida, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.007 · Cited by 1,485 · see citing works

Pathobiology of liver fibrosis: a translational success story

Lee, Y. A., Wallace, M. C., & Friedman, S. L. (2015) · Gut · doi:10.1136/gutjnl-2014-306842 · Cited by 894 · see citing works

Gut-liver axis: Pathophysiological concepts and clinical implications

Tilg, H., Adolph, T. E., & Trauner, M. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.09.017 · Cited by 843 · see citing works

The gut microbiome and liver cancer: mechanisms and clinical translation

Yu, L.-X., & Schwabe, R. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.72 · Cited by 634 · see citing works

Acute-on-chronic liver failure in cirrhosis

Arroyo, V., Moreau, R., Kamath, P. S., Jalan, R., Ginès, P., Nevens, F., Fernández, J., To, U. K., García–Tsao, G., & Schnabl, B. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.41 · Cited by 442 · see citing works

Gut Microbiota Dysbiosis: Triggers, Consequences, Diagnostic and Therapeutic Options

Hrncir, T. (2022) · Microorganisms · doi:10.3390/microorganisms10030578 · Cited by 469 · see citing works

Role of liver sinusoidal endothelial cells in liver diseases

Gracia‐Sancho, J., Caparrós, E., Fernández‐Iglesias, A., & Francés, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00411-3 · Cited by 425 · see citing works

Vascular pathobiology in chronic liver disease and cirrhosis – Current status and future directions

Iwakiri, Y., Shah, V. H., & Rockey, D. C. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.05.047 · Cited by 312 · see citing works

Hepatic microcirculation and mechanisms of portal hypertension

Gracia‐Sancho, J., Marrone, G., & Fernández‐Iglesias, A. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0097-3 · Cited by 288 · see citing works

FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis

Sorribas, M., Jakob, M. O., Yılmaz, B., Li, H., Stutz, D., Noser, Y., Gottardi, A. D., Moghadamrad, S., Hassan, M., Albillos, A., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.017 · Cited by 256 · see citing works

FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis

Verbeke, L., Mannaerts, I., Schierwagen, R., Govaere, O., Klein, S., Vander Elst, I., Windmolders, P., Farre, R., Wenes, M., Mazzone, M., et al. (2016) · Scientific Reports · doi:10.1038/srep33453 · Cited by 236 · see citing works

Bile acid metabolism and signalling in liver disease

Fuchs, C. D., Simbrunner, B., Baumgartner, M., Campbell, C., Reiberger, T., & Trauner, M. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.09.032 · Cited by 246 · see citing works

Gut–liver axis, cirrhosis and portal hypertension: the chicken and the egg

Arab, J. P., Martín‐Mateos, R., & Shah, V. H. (2017) · Hepatology International · doi:10.1007/s12072-017-9798-x · Cited by 229 · see citing works

Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy

Iwakiri, Y., & Trebicka, J. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100316 · Cited by 237 · see citing works

The FXR Agonist Obeticholic Acid Prevents Gut Barrier Dysfunction and Bacterial Translocation in Cholestatic Rats

Verbeke, L., Farre, R., Verbinnen, B., Covens, K., Vanuytsel, T., Verhaegen, J., Komuta, M., Roskams, T., Chatterjee, S., Annaert, P., et al. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2014.10.009 · Cited by 225 · see citing works

Pathogenesis of Alcoholic Liver Disease

Dunn, W., & Shah, V. H. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2016.02.004 · Cited by 221 · see citing works

FXR agonists in NASH treatment

Adorini, L., & Trauner, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.034 · Cited by 197 · see citing works

Biliary bile acids in hepatobiliary injury – What is the link?

Fickert, P., & Wagner, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.04.026 · Cited by 187 · see citing works

The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction

Schwabl, P., Hambruch, E., Seeland, B. A., Hayden, H., Wagner, M., Garnys, L., Strobel, B., Schubert, T.-L., Riedl, F., Mitteregger, D., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.005 · Cited by 178 · see citing works

Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions

Hrncir, T., Hrncirova, L., Kverka, M., Hromádka, R., Machova, V., Trckova, E., Kostovcikova, K., Králíčková, P., Krejsek, J., & Tlaskalová‐Hogenová, H. (2021) · Microorganisms · doi:10.3390/microorganisms9050957 · Cited by 179 · see citing works

CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients

Pockros, P. J., Fuchs, M. A., Freilich, B. L., Schiff, E. R., Kohli, A., Lawitz, E., Hellstern, P. A., Owens-Grillo, J. K., Biene, C. V., Shringarpure, R., et al. (2019) · Liver International · doi:10.1111/liv.14209 · Cited by 161 · see citing works

FXR in liver physiology: Multiple faces to regulate liver metabolism

Panzitt, K., & Wagner, M. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166133 · Cited by 160 · see citing works

SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis

Zhou, J., Cui, S., He, Q., Guo, Y., Pan, X., Zhang, P., Huang, N., Ge, C., Wang, G., Gonzalez, F. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14138-6 · Cited by 154 · see citing works

Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?

Fukui, H. (2019) · Diseases · doi:10.3390/diseases7040058 · Cited by 151 · see citing works

Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis

García‐Lezana, T., Raurell, I., Bravo, M., Torres‐Arauz, M., Salcedo, M. T., Santiago, A., Schoenenberger, A., Manichanh, C., Genescà, J., Martell, M., et al. (2018) · Hepatology · doi:10.1002/hep.29646 · Cited by 136 · see citing works

Breakthroughs in therapies for NASH and remaining challenges

Ratziu, V., Francque, S., & Sanyal, A. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.002 · Cited by 132 · see citing works

Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome

Đanić, M., Stanimirov, B., Pavlović, N., Goločorbin-Kon, S., Al‐Salami, H., Stankov, K., & Mikov, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01382 · Cited by 133 · see citing works

Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis

Sanyal, A. J., Ratziu, V., Loomba, R., Anstee, Q. M., Kowdley, K. V., Rinella, M. E., Sheikh, M. Y., Trotter, J. F., Knapple, W., Lawitz, E. J., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.014 · Cited by 137 · see citing works

Liver resection for cancer: New developments in prediction, prevention and management of postresectional liver failure

van Mierlo, K. M. C., Schaap, F. G., Dejong, C. H. C., & Damink, S. W. M. O. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.06.006 · Cited by 130 · see citing works

The knowns and unknowns of treatment for alcoholic hepatitis

Sehrawat, T. S., Liu, M., & Shah, V. H. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30326-7 · Cited by 127 · see citing works

Bile acids and their receptors in regulation of gut health and diseases

Lin, S., Wang, S., Wang, P., Tang, C., Wang, Z., Chen, L., Luo, G., Chen, H., Liu, Y., Feng, B., et al. (2022) · Progress in Lipid Research · doi:10.1016/j.plipres.2022.101210 · Cited by 123 · see citing works

Current trials and novel therapeutic targets for alcoholic hepatitis

Singal, A. K., & Shah, V. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.026 · Cited by 117 · see citing works

Leaky Gut and Gut-Liver Axis in Liver Cirrhosis: Clinical Studies Update

Fukui, H. (2020) · Gut and Liver · doi:10.5009/gnl20032 · Cited by 115 · see citing works

Pharmacological management of nonalcoholic fatty liver disease

Barb, D., Portillo-Sanchez, P., & Cusi, K. (2016) · Metabolism · doi:10.1016/j.metabol.2016.04.004 · Cited by 114 · see citing works

Review article: therapeutic aspects of bile acid signalling in the gut‐liver axis

Simbrunner, B., Trauner, M. A., & Reiberger, T. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16602 · Cited by 107 · see citing works

Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress

Vairappan, B. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i3.443 · Cited by 106 · see citing works

Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis

Zhou, J., Huang, N., Guo, Y., Cui, S., Ge, C., He, Q., Pan, X., Wang, G., Wang, H., & Hao, H. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.11.004 · Cited by 99 · see citing works

Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease

Abenavoli, L., Falalyeyeva, T. M., Boccuto, L., Tsyryuk, O., & Kobyliak, N. M. (2018) · Pharmaceuticals · doi:10.3390/ph11040104 · Cited by 89 · see citing works

Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis

Goto, T., Itoh, M., Suganami, T., Kanai, S., Shirakawa, I., Sakai, T., Asakawa, M., Yoneyama, T., Kai, T., & Ogawa, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-26383-8 · Cited by 88 · see citing works

FXR modulators for enterohepatic and metabolic diseases

Wang, H., He, Q., Wang, G., Xu, X., & Hao, H. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1527906 · Cited by 88 · see citing works

Recent advances on FXR-targeting therapeutics

Panzitt, K., Zollner, G., Marschall, H., & Wagner, M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111678 · Cited by 86 · see citing works

Pathophysiology and therapeutic options for cirrhotic portal hypertension

Guixé‐Muntet, S., Quesada‐Vázquez, S., & Gracia‐Sancho, J. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00438-7 · Cited by 86 · see citing works

New drugs for NAFLD: lessons from basic models to the clinic

Reimer, K. C., Wree, A., Roderburg, C., & Tacke, F. (2019) · Hepatology International · doi:10.1007/s12072-019-10001-4 · Cited by 83 · see citing works

Systemic Inflammation and Acute-on-Chronic Liver Failure: Too Much, Not Enough

Laleman, W., Clària, J., der Merwe, S. V., Moreau, R., & Trebicka, J. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/1027152 · Cited by 74 · see citing works

Bile acid receptors and nonalcoholic fatty liver disease

Yuan, L. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i28.2811 · Cited by 82 · see citing works

Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders

Fiorucci, S., Giorgio, C. D., & Distrutti, E. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_227 · Cited by 82 · see citing works

Perspectives on Treatment for Nonalcoholic Steatohepatitis

Lassailly, G., Caiazzo, R. J., Pattou, F. N., & Mathurin, P. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.004 · Cited by 82 · see citing works

Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities

Radun, R., & Trauner, M. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1731707 · Cited by 81 · see citing works

Direct and Indirect Effects of Fibroblast Growth Factor (FGF) 15 and FGF19 on Liver Fibrosis Development

Schumacher, J. D., Kong, B., Wu, B. J., Rizzolo, D., Armstrong, L. E., Chow, M. D., Goedken, M. J., Lee, Y., & Guo, G. L. (2019) · Hepatology · doi:10.1002/hep.30810 · Cited by 80 · see citing works

Nonsteroidal FXR Ligands: Current Status and Clinical Applications

Gege, C., Hambruch, E., Hambruch, N., Kinzel, O., & Kremoser, C. (2019) · Handbook of Experimental Pharmacology · doi:10.1007/164_2019_232 · Cited by 83 · see citing works

Novel perspectives in the management of decompensated cirrhosis

Bernardi, M., & Caraceni, P. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0045-2 · Cited by 79 · see citing works

Gut microbiome determines therapeutic effects of OCA on NAFLD by modulating bile acid metabolism

Liu, J., Sun, J., Yu, J., Chen, H., Zhang, D., Zhang, T., Ma, Y., Zou, C., Zhang, Z., Ma, L., et al. (2023) · npj Biofilms and Microbiomes · doi:10.1038/s41522-023-00399-z · Cited by 82 · see citing works

Obeticholic acid protects against carbon tetrachloride‐induced acute liver injury and inflammation

Zhang, D.-G., Zhang, C., Wang, J.-X., Wang, B.-W., Wang, H., Zhang, Z.-H., Chen, Y.-H., Lu, Y., Tao, L., Wang, J.-Q., et al. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.11.006 · Cited by 75 · see citing works

Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities

Manka, P. P., Zeller, A. C., & Syn, W. (2019) · Drugs · doi:10.1007/s40265-019-01126-9 · Cited by 77 · see citing works

Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension

Mookerjee, R. P., Mehta, G., Vairappan, B., Mohamed, F. E. Z. A., Davies, N. A., Sharma, V., Iwakiri, Y., & Jalan, R. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.08.024 · Cited by 74 · see citing works

FXR agonists for NASH: How are they different and what difference do they make?

Kremoser, C. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.03.020 · Cited by 72 · see citing works

Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Clinical and Research Implications

Lonardo, A., Mantovani, A., Targher, G., & Baffy, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113320 · Cited by 75 · see citing works

Clinical and metabolic effects associated with weight changes and obeticholic acid in non‐alcoholic steatohepatitis

Hameed, B., Terrault, N. A., Gill, R. M., Loomba, R. S., Chalasani, N., Hoofnagle, J. H., Natta, M. L. V., & CRN, F. T. N. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14492 · Cited by 73 · see citing works

The non-steroidal FXR agonist cilofexor improves portal hypertension and reduces hepatic fibrosis in a rat NASH model

Schwabl, P., Hambruch, E., Budas, G. R., Supper, P., Burnet, M., Liles, J. T., Birkel, M., Brusilovskaya, K., Königshofer, P., Peck-Radosavljevic, M., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9010060 · Cited by 70 · see citing works

Taurocholic acid promotes hepatic stellate cell activation via S1PR2/p38 MAPK/YAP signaling under cholestatic conditions

Yang, J., Tang, X., Zhu, L., Chen, M., & Sun, L. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0327 · Cited by 70 · see citing works

Spontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liver

Lutz, P. L. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i3.304 · Cited by 65 · see citing works

Role of farnesoid X receptor in inflammation and resolution

Shaik, F. B., Prasad, D. V. R., & Narala, V. R. (2014) · Inflammation Research · doi:10.1007/s00011-014-0780-y · Cited by 67 · see citing works

Bile acids at the cross-roads of gut microbiome–host cardiometabolic interactions

Ryan, P. M., Stanton, C., & Caplice, N. M. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0299-9 · Cited by 67 · see citing works

Bile acids and cardiovascular function in cirrhosis

Voiosu, A. M., Wiese, S. S., Voiosu, T. A., Bendtsen, F., & Møller, S. (2017) · Liver International · doi:10.1111/liv.13394 · Cited by 66 · see citing works

Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis

Greuter, T., Malhi, H., Gores, G. J., & Shah, V. H. (2017) · JCI Insight · doi:10.1172/jci.insight.95354 · Cited by 67 · see citing works

Gut Microbiota and Host Reaction in Liver Diseases

Fukui, H. (2015) · Microorganisms · doi:10.3390/microorganisms3040759 · Cited by 64 · see citing works

Obeticholic acid for the treatment of primary biliary cirrhosis

Trivedi, P. J., Hirschfield, G. M., & Gershwin, M. E. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1092381 · Cited by 65 · see citing works

Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis

Schumacher, J. D., & Guo, G. L. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_228 · Cited by 64 · see citing works

Farnesoid X Receptor Activation Attenuates Intestinal Ischemia Reperfusion Injury in Rats

Ceulemans, L. J., Verbeke, L., Decuypere, J.-P., Farré, R., Hertogh, G. D., Lenaerts, K., Jochmans, I., Monbaliu, D. R. L., Nevens, F., Tack, J. F., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169331 · Cited by 62 · see citing works

Role of bile acids in the diagnosis and progression of liver cirrhosis: A prospective observational study

Liu, N., Feng, J., Lv, Y., Liu, Q., Deng, J., Xia, Y., Guo, C., & Zhou, Y. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.8011 · Cited by 62 · see citing works

Liver fibrosis: the 2017 state of art

Caviglia, G. P., Rosso, C., Fagoonee, S., Saracco, G. M., & Pellicano, R. (2017) · Panminerva Medica · doi:10.23736/s0031-0808.17.03359-6 · Cited by 60 · see citing works

Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease

Baffy, G. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4903-5 · Cited by 61 · see citing works

Potential mechanisms linking gut microbiota and portal hypertension

Baffy, G. (2018) · Liver International · doi:10.1111/liv.13986 · Cited by 59 · see citing works

New cellular and molecular targets for the treatment of portal hypertension

Gracia‐Sancho, J., Maeso‐Díaz, R., Fernández‐Iglesias, A., Navarro-Zornoza, M., & Bosch, J. (2015) · Hepatology International · doi:10.1007/s12072-015-9613-5 · Cited by 58 · see citing works

A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction

An, P., Wei, G., Huang, P., Li, W., Qi, X., Lin, Y., Vaid, K. A., Wang, J., Zhang, S., Li, Y., et al. (2020) · Liver International · doi:10.1111/liv.14490 · Cited by 57 · see citing works

Cholangiopathies – Towards a molecular understanding

Tam, P. K. H., Yiu, R. S. W., Lendahl, U., & Andersson, E. R. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.024 · Cited by 54 · see citing works

The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease

Zhang, D., Zhu, L., Liu, H., Tseng, Y., Weng, S., Liu, T., Dong, L., & Shen, X. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s207277 · Cited by 54 · see citing works

Managing portal hypertension in patients with liver cirrhosis

Sauerbruch, T., Schierwagen, R., & Trebicka, J. (2018) · F1000Research · doi:10.12688/f1000research.13943.1 · Cited by 51 · see citing works

Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction

Sauerbruch, T., Hennenberg, M., Trebicka, J., & Beuers, U. H. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.718783 · Cited by 51 · see citing works

Primary biliary cholangitis as a roadmap for the development of novel treatments for cholestatic liver diseases†

Nevens, F., Trauner, M. A., & Manns, M. P. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.007 · Cited by 51 · see citing works

Metformin reduces hepatic resistance and portal pressure in cirrhotic rats

Tripathi, D. M., Erice, E., Lafoz, E., García‐Calderó, H., Sarin, S. K., Bosch, J., Gracia‐Sancho, J., & García‐Pagán, J. C. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00010.2015 · Cited by 48 · see citing works

Pathophysiology and management of liver cirrhosis: from portal hypertension to acute-on-chronic liver failure

Jagdish, R. K., Roy, A., Kumar, K., Premkumar, M., Sharma, M., Rao, P. N., Reddy, D. N., & Kulkarni, A. V. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1060073 · Cited by 47 · see citing works

Intercellular crosstalk of liver sinusoidal endothelial cells in liver fibrosis, cirrhosis and hepatocellular carcinoma

Li, H. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.07.006 · Cited by 47 · see citing works

Bile acids: emerging role in management of liver diseases

Asgharpour, A., Kumar, D. P., & Sanyal, A. J. (2015) · Hepatology International · doi:10.1007/s12072-015-9656-7 · Cited by 46 · see citing works

Farnesoid X receptor signaling activates the hepatic X‐box binding protein 1 pathway in vitro and in mice

Liu, X., Guo, G. L., Kong, B., Hilburn, D. B., Hubchak, S. C., Park, S., LeCuyer, B. E., Hsieh, A., Wang, L., Fang, D., et al. (2018) · Hepatology · doi:10.1002/hep.29815 · Cited by 46 · see citing works

Metabolic Effects of Bile Acids: Potential Role in Bariatric Surgery

Flynn, C. R., Albaugh, V. L., & Abumrad, N. N. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.04.014 · Cited by 46 · see citing works

Emerging medical therapies for non-alcoholic fatty liver disease and for alcoholic hepatitis

Wong, V. W., & Singal, A. K. (2019) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.06.06 · Cited by 45 · see citing works

Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches

Mohammed, O. S., Attia, H. G., Mohamed, B. M. S. A., Elbaset, M. A., & Fayed, H. M. (2023) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2023.11808 · Cited by 46 · see citing works

Plasma Exchange in Acute and Acute on Chronic Liver Failure

Maiwall, R., & Sarin, S. (2021) · Seminars in liver disease (Print) · doi:10.1055/s-0041-1730971 · Cited by 38 · see citing works

Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection

Bowlus, C. L. (2016) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s91709 · Cited by 43 · see citing works

New developments in the treatment of primary biliary cholangitis – role of obeticholic acid

Jhaveri, M. A., & Kowdley, K. V. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s113052 · Cited by 44 · see citing works

Nonalcoholic fatty liver disease and portal hypertension

Ryou, M. K., Stylopoulos, N., & Baffy, G. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00011 · Cited by 43 · see citing works

A nonbile acid farnesoid X receptor agonist tropifexor potently inhibits cholestatic liver injury and fibrosis by modulating the gut–liver axis

Xiao, Y., Wang, Y., Liu, Y., Wang, W., Tian, X., Chen, S., Lu, Y., Du, J., & Cai, W. (2021) · Liver International · doi:10.1111/liv.14906 · Cited by 43 · see citing works

Pharmacologic Management of Portal Hypertension

Berzigotti, A., & Bosch, J. (2014) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.12.003 · Cited by 42 · see citing works

Interplay of Matrix Stiffness and c-SRC in Hepatic Fibrosis

Görtzen, J., Schierwagen, R., Bierwolf, J., Klein, S., Uschner, F. E., van der Ven, P. F. M., Fürst, D. O., Strassburg, C. P., Laleman, W., Pollok, J., et al. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00359 · Cited by 42 · see citing works

Novel Pharmacotherapy Options for NASH

Ratziu, V. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4128-z · Cited by 41 · see citing works

Pyrazinamide Induced Rat Cholestatic Liver Injury through Inhibition of FXR Regulatory Effect on Bile Acid Synthesis and Transport

Guo, H., Hassan, H. M., Zhang, Y., Dong, S.-Z., Ding, P., Wang, T., Sun, L., Zhang, L., & Jiang, Z. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw098 · Cited by 41 · see citing works

The Hepatic Sinusoid in Chronic Liver Disease: The Optimal Milieu for Cancer

Gibert‐Ramos, A., Sanfeliu-Redondo, D., Aristu-Zabalza, P., Martínez-Alcocer, A., Gracia‐Sancho, J., Guixé‐Muntet, S., & Fernández‐Iglesias, A. (2021) · Cancers · doi:10.3390/cancers13225719 · Cited by 43 · see citing works

Obeticholic acid, a Farensoid-X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats

Verbeke, L., Trebicka, J., & Laleman, W. (2014) · Hepatology · doi:10.1002/hep.27125 · Cited by 1 · see citing works

Obeticholic acid: A new light in the shadows treating portal hypertension?

Gracia‐Sancho, J., Hernández–Gea, V., & García‐Pagán, J. C. (2014) · Hepatology · doi:10.1002/hep.27027 · Cited by 3 · see citing works

The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction

Schwabl, P., Hambruch, E., Seeland, B. A., Hayden, H., Wagner, M., Garnys, L., Strobel, B., Schubert, T.-L., Riedl, F., Mitteregger, D., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.005 · Cited by 178 · see citing works

Activation of farnesoid X receptor (FXR) by its agonist int-747 restores hepatic endothelial NOS activity and lowers portal pressure in cirrhotic rats by modulating the DDAH-ADMA pathway

Vairappan, B., Sharma, V., Davies, N. A., Jalan, R., & Mookherjee, R. (2013) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2013.03.025 · Cited by 1 · see citing works

Membrane microdomains in regulated secretion in endothelial cells

Gerke, V. (2011) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2011.05.058